



Watterson, K. R., Hudson, B. D., Ulven, T., and Milligan, G. (2014) Treatment of type 2 diabetes by free fatty acid receptor agonists. *Frontiers in Endocrinology* . ISSN 1664-2392

Copyright © 2014 The Authors

<http://eprints.gla.ac.uk/96202>

Deposited on: 19 August 2014

Enlighten – Research publications by members of the University of Glasgow_
<http://eprints.gla.ac.uk>

Treatment of type 2 diabetes by free fatty acid receptor agonists

Kenneth R Watterson, Brian D Hudson, Trond Ulven and Graeme Milligan

Journal Name:	Frontiers in Endocrinology
ISSN:	1664-2392
Article type:	Review Article
Received on:	27 Jun 2014
Accepted on:	07 Aug 2014
Provisional PDF published on:	07 Aug 2014
www.frontiersin.org:	www.frontiersin.org
Citation:	Watterson KR, Hudson BD, Ulven T and Milligan G(2014) Treatment of type 2 diabetes by free fatty acid receptor agonists. <i>Front. Endocrinol.</i> 5:137. doi:10.3389/fendo.2014.00137
Copyright statement:	© 2014 Watterson, Hudson, Ulven and Milligan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

This Provisional PDF corresponds to the article as it appeared upon acceptance, after rigorous peer-review. Fully formatted PDF and full text (HTML) versions will be made available soon.

Treatment of type 2 diabetes by free fatty acid receptor agonists

Abbreviated title: FFA receptor agonists and diabetes

Kenneth R. Watterson¹, Brian D. Hudson¹, Trond Ulven² and Graeme Milligan^{1*}

¹Molecular Pharmacology Group, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Scotland, U.K.

²Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, Odense M, Denmark

Correspondence:

Prof Graeme Milligan
Molecular Pharmacology Group,
Institute of Molecular, Cell and Systems Biology,
College of Medical, Veterinary and Life Sciences,
University of Glasgow,
Glasgow G12 8QQ,
Scotland, U.K.

Graeme.Milligan@glasgow.ac.uk

Keywords: diabetes, FFA receptor, insulin, incretin, inflammation

Figures: 2

Tables: 1

Word count: 3595

Abstract

Dietary free fatty acids (FFAs), such as ω -3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors. Selective synthetic ligands for Free Fatty Acid receptors (FFA1-4) have consequently been developed as potential treatments for type 2 diabetes (T2D). In particular, clinical studies show that Faslifam, an agonist of the long chain FFA receptor, FFA1, improved glycaemic control and reduced HbA1c levels in T2D patients, with a reduced risk of hypoglycemia. However, this ligand was removed from clinical trials due to potential liver toxicity and determining if this is a target or a ligand-specific feature is now of major importance. Pre-clinical studies also show that FFA4 agonism increases insulin sensitivity, induces weight loss and reduces inflammation and the metabolic and anti-inflammatory effects of short chain fatty acids (SCFAs) are linked with FFA2 and FFA3 activation. In this review, we therefore show that FFA receptor agonism is a potential clinical target for T2D treatment and discuss ongoing drug development programmes within industry and academia aimed at improving the safety and effectiveness of these potential treatments.

Introduction

In 2013, 382 million people worldwide were characterised as diabetics with around 90% of patients diagnosed with type 2 diabetes (T2D), a metabolic disorder intrinsically linked with obesity (Alberti and Zimmet, 2014). T2D is defined by insulin resistance in peripheral tissues, such as the liver and muscle, and a loss of pancreatic beta-cell function, resulting in insufficient insulin secretion (McCarthy, 2010) and constitutes a risk factor for health issues including cardiovascular disease, impaired wound healing, blindness, and renal failure (Alberti and Zimmet, 2014). Although T2D can sometimes be controlled through strict diet regulation, a large number of patients require clinical therapies. Current treatments, such as metformin, sulfonylureas, glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, are deployed primarily to either improve insulin secretion, peripheral insulin sensitivity or both (Majumdar and Inzucchi, 2013). However, there remains a demand for distinct, safe and effective treatments for T2D, with the current therapies often associated with side effects including hypoglycemia and weight gain. Naturally occurring free fatty acids (FFAs) found in the diet, including ω -3 fatty acids, have profound effects on metabolic and inflammatory processes associated with T2D, although the molecular basis for these effects are complex and incompletely understood (Offermanns, 2014). FFAs are classified based upon their chain length, such that short chain fatty acids (SCFAs) have 1-6 carbon atoms; medium chain fatty acids (MCFAs) contains 7-12 carbon atoms and long-chain fatty acids (LCFAs) contain more than 12 carbon atoms (Offermanns, 2014). Many of the biological effects of FFAs have now been attributed, at least in part, to FFAs interacting with a group of G protein-coupled receptors (GPCRs) designated the FFA receptors. The most well characterised FFA receptors are the two LCFA-specific receptors, FFA1 and FFA4, and the SCFA-specific receptors FFA2 and FFA3. FFA receptor agonism, particularly of the FFA1 receptor, has subsequently been shown to have beneficial metabolic effects (Offermanns, 2014). Consequently, a number of ongoing industrial and academic programmes are focused upon developing potent and selective synthetic agonists of FFA1. Although currently less developed, activation of each of FFA2, FFA3 and FFA4 has also been suggested to have potential benefits for metabolic function. In this review, we will therefore discuss the potential of FFA receptor agonists as novel clinical treatments for T2D.

FFA1

FFA1, activated by various saturated (e.g. palmitic acid, C16:0), mono-unsaturated (e.g. oleic acid, C18:1) and polyunsaturated long chain FFAs (e.g. linoleic acid, C18:2) (Table 1), is a $G_{q/11}$ -coupled GPCR predominantly expressed in pancreatic beta cells, that is associated with increased glucose-stimulated insulin secretion (GSIS) (Offermanns, 2014, Ferdaoussi et al., 2012, Latour et al., 2007) (Figure 1). FFA1 is also expressed by various enteroendocrine cells where it regulates the release of incretin hormones such as glucagon-like peptide-1 (GLP-1), an insulinotropic, anorectic peptide that reduces gastric emptying and motility, as well as cholecystokinin (CCK), shown to regulate pancreatic secretion, inhibit gastric motility and reduce energy intake (Houze et al., 2012, Luo et al., 2012, Liou et al., 2011, Edfalk et al., 2008) (Figure 1). FFA1 is also present within the central nervous system (CNS) (Nakamoto et al., 2013, Ma et al., 2007) although whether neuronal FFA1 contributes to the regulation of glucose homeostasis remains to be fully determined

(Figure 1). FFA1 expression has also been reported in glucagon-producing alpha cells within the pancreas, although this remains controversial (Flodgren et al., 2007, Wang et al., 2011, Itoh et al., 2003, Lan et al., 2008, Hirasawa et al., 2008). FFA1 expression has also been well characterised in taste buds where it mediates, in part, taste preference for fatty acids, although the significance of this, and possible effects of pharmacological activation or blockade, remains to be fully elucidated (Cartoni et al., 2010, Gilbertson and Khan, 2014) (Figure 1).

FFA1 and insulin secretion

Acute FFA-mediated insulin secretion from isolated human and rodent islets involves amplification of the second phase of GSIS (Latour et al., 2007, Ferdaoussi et al., 2012, Kebede et al., 2012, Itoh et al., 2003). This is reduced by approximately 50% in FFA1-null mice, with the remaining effect attributed to intracellular metabolism of FFAs (Latour et al., 2007, Ferdaoussi et al., 2012, Kebede et al., 2012, Itoh et al., 2003). In contrast, transgenic overexpression of FFA1 under the control of the mouse insulin II promoter prevents development of hyperglycemia and improves insulin secretion and glucose tolerance in diabetic mouse models (Nagasumi et al., 2009). As anticipated from this, GW9508, a synthetic FFA1 agonist (Table 1), stimulated GSIS in pancreatic MIN6 cells (Briscoe et al., 2006). FFA1 gene expression is also reduced under glucolipotoxic conditions in rats and in islets from T2D patients whilst a rare mutation in the human FFA1 gene is associated with attenuated lipid-mediated enhancement of GSIS (Del Guerra et al., 2010, Fontes et al., 2010, Walker et al., 2011). The effects of FFA1 on pancreatic beta cell viability, however, has been controversial, with pancreatic-specific FFA1 overexpression associated with disrupted islet morphology and impaired beta cell function whereas FFA1 disruption is linked with increased beta cell viability in mice fed on a High Fat Diet (HFD) (Steneberg et al., 2005). These observations promoted the concept that, at least in the longer term, FFA1 antagonism could be beneficial in the treatment of diabetes. However, most subsequent preclinical studies contradict these findings, indicating that FFA1 agonism has no detrimental effects on beta cell viability (Nagasumi et al., 2009, Kebede et al., 2012, Lan et al., 2008), or even protects beta cells (Zhang et al., 2007, Wu et al., 2010, Wagner et al., 2013).

The FFA1 agonist Fasiglifam and insulin secretion

Although there are currently no FFA1 agonists approved for clinical use, considerable interest developed around Fasiglifam (designated TAK-875 in pre-clinical studies, Figure 2), an orally available FFA1 agonist developed by Takeda (Yashiro et al., 2012, Tsujihata et al., 2011, Araki et al., 2012) (Table 1). Completed Phase II clinical trials demonstrated that T2D patients treated with Fasiglifam had reduced blood glucose levels, increased insulin levels and resulted in a 1.2–1.4% reduction in haemoglobin A1c (HbA1c) levels (Mancini and Poitout, 2013, Burant et al., 2012, Naik et al., 2012, Araki et al., 2012, Leifke et al., 2012) (Table 1). Crucially, although these effects were comparable to current sulfonylurea treatments, Fasiglifam was associated with markedly less side effects, with no significant increases in body weight and a reduced concomitant incidence of hypoglycaemia (Mancini and Poitout, 2013, Burant et al., 2012, Naik et al., 2012, Araki et al., 2012, Leifke et al., 2012). This is consistent with pre-clinical data demonstrating that Fasiglifam improved fasting hyperglycemia and glucose tolerance and augmented GSIS in diabetic rat models, with no hypoglycaemia

observed in normoglycemic rats (Tsujiyata et al., 2011). No changes in insulin resistance have been reported in response to Fasiglifam treatment (Burant, 2013, Bailey, 2012) and Fasiglifam had no effect on glucagon secretion in isolated human islets and did not alter glucagon levels in T2D patients (Poitout and Lin, 2013). Importantly, prolonged Fasiglifam exposure was also not associated with beta cell dysfunction or apoptosis (Tsujiyata et al., 2011).

The effect of partial vs. full FFA1 agonists on incretin release from enteroendocrine cells

The ability of synthetic FFA1 agonists to induce significant incretin release was recently shown to depend upon whether the compound was a partial or full agonist (Luo et al., 2012, Edfalk et al., 2008, Lin et al., 2012a) (Figure 1). In this regard, TAK-875/Fasiglifam had no effect on incretin release from enteroendocrine cells with similar results reported for AMG-837 (Amgen, Table 1, Figure 2) (Poitout and Lin, 2013). In contrast, Amgen described AM-1638 and AM-5262 (Table 1, Figure 2) as full FFA1 agonists that directly stimulate insulin secretion and promote incretin release from enteroendocrine cells (Brown et al., 2012, Wang et al., 2013, Poitout and Lin, 2013) (Figure 1). This incretin-stimulating effect was abolished in FFA1 knockout mice and the effect of AM-1638 on glucose homeostasis was attenuated by the GLP-1R antagonist, Ex(9–39)NH₂, indicating a particularly key role for GLP-1 (Poitout and Lin, 2013). Similarly, LY2881835, a full FFA1 agonist from Eli Lilly (Table 1), increased GSIS, lowered blood glucose levels and increased GLP-1 secretion in animal models (Defossa and Wagner, 2014). Amgen demonstrated that multiple ligand binding pockets exist on FFA1, comprising of up to two allosteric sites as well as the FFA binding orthosteric site (Lin et al., 2012a). One allosteric site is targeted by compounds such as AM-837 and TAK-875 whilst the second allosteric site is a target for receptor agonists such as AM-1638 that act as full agonists. Consequently, positive co-operativity was shown between either AMG-837 or AM-1638 in conjunction with natural FFA ligands in cell based assays measuring second-messenger generation, as well as primary cell based assays, with positive co-operativity also reported between AMG-837 and AM-1638 during an oral glucose tolerance test in a diabetic rodent model (Lin et al., 2012a)

FFA1 agonists: Ongoing FFA1 drug programmes and future challenges

Although no issues were raised regarding safety and tolerability during Phase I and II trials, Fasiglifam was recently withdrawn from phase III trials due to potential liver toxicity (Defossa and Wagner, 2014) (Table 1). Similarly, Amgen and Eli Lilly removed AMG-837 and LY2881835 (Table 1, Figure 2) respectively from Phase I clinical trials due to concerns over toxicity (Defossa and Wagner, 2014). However, the preclinical and clinical data generated using Fasiglifam provides a strong rationale and validation for further studies into the potential use of FFA1 agonism as a novel treatment for T2D. Currently, Japan Tobacco are conducting Phase II clinical trials with their FFA1 agonist candidate, JTT-851 and Piramal have begun Phase I clinical trials on their FFA1 agonist, P11187 (Defossa and Wagner, 2014) (Table 1). Daiichi Sanyo also recently described 3-aryl-3-ethoxypropanoic acids as orally active FFA1 agonists that improve insulin secretion and glucose homeostasis in rats (Takano et al., 2014). Additionally, FFA1 agonists developed by Astellas are reported to have beneficial effects on glucose homeostasis in diabetic mouse models (Tanaka et al.,

2014, Tanaka et al., 2013). Sanofi and Boehringer-Ingelheim are also reported to have FFA1 agonist programmes under development (Defossa and Wagner, 2014). In an academic context, the University of Southern Denmark have developed 4-(benzylamine)hydrocinnamic acid FFA1 agonists such as TUG-469 (Christiansen et al., 2010, Christiansen et al., 2012) and 4-alkynehydrocinnamic acid FFA1 agonists, including TUG-424, and TUG-770 (Christiansen et al., 2013b, Christiansen et al., 2008, Urban et al., 2013) (Table 1). Within these programmes, several strategies have been followed to reduce compound lipophilicity (Christiansen et al., 2011, Christiansen et al., 2012, Christiansen et al., 2013a). Consequently, TUG-770 (Figure 2) has recently been described as a highly potent FFA1 agonist with favourable physicochemical and pharmacokinetic properties, improving glucose tolerance in diet-induced obese mice. This effect did not desensitise, being fully maintained after 29 days of chronic dosing (Christiansen et al., 2013b).

FFA4

FFA4, a G_q-coupled GPCR activated by LCFAs, including α -linolenic acid (α -LA) and docosahexaenoic acid (DHA) (Table 1), is expressed in enteroendocrine cells, lung, brain, white adipose tissues, heart and liver (Offermanns, 2014). Within adipose tissue, FFA4 gene expression is upregulated following a HFD and FFA4 activation in adipocytes is associated with increased adipogenesis and glucose uptake (Cornall et al., 2014, Hudson et al., 2013b, Oh et al., 2010), suggesting that FFA4 activation may promote adiposity and obesity (Figure 1). However, mutation of FFA4 (p.R270H variant) is associated with an increased risk of obesity in European populations, (although this variant is almost absent in a Japanese population) and young FFA4 null mice fed a HFD gained significantly more fat mass than their wild-type littermates, suggesting that FFA4 protects against diet-induced obesity (Ichimura et al., 2012). FFA4 agonism is also commonly associated with improved insulin sensitivity, with FFA4 null mice reported to have increased fasting glucose and impaired responses to insulin and glucose tolerance testing (Ichimura et al., 2012, Oh et al., 2010) (Figure 1). A number of these metabolic effects, such as increased insulin secretion, satiety, and improved glycemic control, have been attributed, at least in part, to FFA4-dependent incretin release from enteroendocrine cells, particularly GLP-1 (Hirasawa et al., 2005, Cornall et al., 2014, Offermanns, 2014, Hudson et al., 2013b) (Figure 1). GLP-1 secretion was demonstrated both *in vitro* and *in vivo* using α LA as an agonist (Hirasawa et al., 2005). Similarly, TUG-891 (Figure 2), a potent FFA4 agonist (see below), also increased GLP-1 secretion from STC-1 and GLUTag enteroendocrine cells (Hudson et al., 2013b). However, a recent study has questioned the significance of FFA4-mediated GLP-1 release (Paulsen et al., 2014). FFA4 also co-localises with the orexigenic peptide, ghrelin, in duodenal cells *in vivo*, with recent studies showing that FFA4 activation inhibits ghrelin secretion (Engelstoft et al., 2013, Gong et al., 2014). An emerging role for FFA4 within pancreatic islets has also recently developed, with the pancreatic islets of diabetic and hyperglycaemic individuals shown to have decreased levels of FFA4 mRNA and knockdown of FFA4 mRNA levels within islets demonstrated to attenuate the protective effects of the ω -3 fatty acid, eicosapentaenoic acid against palmitate-induced cell apoptosis (Taneera et al., 2012) (Figure 1). FFA4 expression has also recently been detected in delta cells and alpha cells within the pancreas and was consequently linked with the inhibition of glucose-dependent somatostatin release and the regulation of glucagon secretion respectively (Stone et al., 2014, Suckow et al., 2014) (Figure 1). Similar to FFA1,

FFA4 is also expressed in taste buds and is linked with the regulation of taste preference although, again, the significance of this in relation to obesity and T2D remains to be clarified (Abdoul-Azize et al., 2014) (Figure 1).

The anti-inflammatory effects of FFA4

A recent study indicated that, in addition to the previously described insulin-sensitising effects associated with GLP-1 release, improved systemic insulin sensitivity may also be associated with FFA4-mediated anti-inflammatory effects on macrophages (Oh et al., 2010) (Figure 1). In this study, FFA4 expression in macrophages was elevated in response to obesity and FFA4 activation decreased pro-inflammatory gene expression in M1 macrophages and increased expression of M2 anti-inflammatory genes with reduced macrophage infiltration of adipose tissues also observed in FFA4 null mice due to decreased chemotaxis (Oh et al., 2010). These anti-inflammatory effects are largely associated with FFA4-mediated recruitment of beta-arrestin 2, a scaffold protein typically associated with receptor desensitisation and internalisation that is also implicated in the regulation of distinct signalling pathways (Oh et al., 2010, Halder et al., 2013, Li et al., 2013). In the case of FFA4, beta-arrestin 2 interacts with TAB1 that, in turn, inhibits lipopolysaccharide (LPS)- and tumour necrosis factor (TNF)-alpha-induced TAK1 stimulation, thereby blocking toll-like receptor 4 (TLR4) and the TNF-alpha inflammatory pathways (Oh et al., 2010, Halder et al., 2013, Li et al., 2013). Interestingly, recent studies have also reported FFA4-mediated anti-inflammatory effects within the brain. In particular, FFA4 has been associated with the anti-inflammatory effects of ω -3 and ω -9 fatty acids in the hypothalamus, thereby reducing diet-induced inflammation and reducing body adiposity (Cintra et al., 2012, Wellhauser and Belsham, 2014) (Figure 1).

Synthetic FFA4 agonists

Initial synthetic FFA4 agonists, including GW9508, NCG21 (Figure 2) and NCG46 (Table 1), showed significant dual agonism at FFA1 (Holliday et al., 2011). However, our groups have recently reported on TUG-891, a potent and selective FFA4 agonist (Hudson et al., 2013b, Shimpukade et al., 2012) (Table 1, Figure 2), although TUG-891 is significantly less selective for murine FFA4 compared to murine FFA1, potentially limiting its use in preclinical *in vivo* studies in mice (Shimpukade et al., 2012). Recent modelling and mutational efforts have, however, clearly defined how TUG-891 interacts with FFA4 (Hudson et al., 2014b), information that will be invaluable in developing novel ligands with improved pharmacological properties for this receptor. To date, no FFA4 agonists have entered clinical trials although a number of FFA4 agonist programmes are ongoing. For example, Banyu Pharmaceutical Co. Ltd, IRM LLC USA, Metabolex, Inc, Kindex Therapeutics, and Pharma Frontier Co. Ltd have all patented FFA4 agonists for the treatment of metabolic and inflammatory disease (Halder et al., 2013) (Table 1). Similarly, GSK has recently described a series of diarylsulfonamides as FFA4 agonists (Sparks et al., 2014) and Metabolex has reported that their series of dihydrobenzofuran-based FFA4 agonists improved glucose homeostasis in mice, with moderate glucose-lowering effects in mice shown with a separate series of FFA4 agonists (Halder et al., 2013). Additionally, Kindex Therapeutics described beneficial effects in the treatment of obesity, inflammation, and metabolic disorders with alpha acids that were reported to act both as FFA4 agonists and also as partial PPAR γ agonists (Halder et al., 2013).

Metabolic regulation by FFA2 and FFA3

High fibre intake protects against obesity and T2D via SCFA production, particularly butyrate, acetate and propionate, from bacterial fermentation of dietary fibre in the large intestine (Cani et al., 2013). Moreover, modulation of gut microbiota using pre- and probiotics in both mice and humans regulates body weight, appetite and glucose homeostasis (Cani et al., 2013). These SCFA-mediated beneficial effects on body weight and glucose homeostasis in HFD-fed mice are due, at least in part, to FFA2/FFA3-dependent mechanisms, including for example increased secretion of incretins, such as GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and peptide YY (PYY) (Nohr et al., 2013, Cani et al., 2013). These receptors are activated by the SCFAs produced by fibre fermentation in the gut, with the human FFA2 orthologue preferentially activated by shorter SCFAs, such as acetate, whereas human FFA3 is activated preferentially by the longer SCFAs, with propionate being the most potent SCFA for both receptors, at least in human (Offermanns, 2014, Cani et al., 2013, Nohr et al., 2013, Tolhurst et al., 2012, Brown et al., 2003, Le Poul et al., 2003, Nilsson et al., 2003, Schmidt et al., 2011) (Table 1, Figure 1). However, the relative potency and preference for various SCFAs appears to vary significantly across species (Hudson et al., 2012a, Hudson et al., 2012b). SCFA-triggered secretion of GLP-1 was almost completely abolished in primary colonic cultures from FFA2 null mice and reduced, to a lesser extent, in mice lacking FFA3 (Tolhurst et al., 2012). FFA2 is expressed in adipose tissue, intestine, islet cells, enteroendocrine cells and immune cells whilst FFA3 is highly expressed in the small intestine, colon, and pancreas (Offermanns, 2014). FFA2 expression levels are also elevated in the skeletal muscle, liver, and adipose tissue of HFD-fed rodents, with FFA2 shown to regulate adipogenesis and adipocyte differentiation and inhibit lipolysis (Bindels et al., 2013) (Figure 1).

Complete elucidation of the metabolic effects of FFA2 and FFA3 has, however, been complicated by conflicting results using FFA2 and FFA3 null mice. For example, in one study, HFD-fed FFA2 null mice display lower body fat mass and improved glucose control compared to wild type mice, indicating a role for FFA2 antagonists in the treatment of T2D (Bjursell et al., 2011). Contrastingly, FFA2 null mice were also shown to be obese on a normal diet, with reduced insulin sensitivity and marked insulin resistance whereas adipocyte-specific overexpression of FFA2 resulted in lower body weight in a HFD study (Kimura et al., 2013). Similarly, the loss of FFA3 either resulted in weight loss, obesity or had no effect in different studies (Zaibi et al., 2010, Samuel et al., 2008, Lin et al., 2012b). Hence, the development of more potent and selective FFA2 and FFA3 agonists will hopefully facilitate the elucidation of the metabolic effects of FFA2 and FFA3 and ultimately provide future treatments for T2D. Several selective compound series are already known, especially for FFA2 (Ulven, 2012) (Table 1). Small carboxylic acids derived from the natural SCFA ligands have shown appreciable and predictable selectivity but have low potency (Schmidt et al., 2011). Selective allosteric agonists of FFA2 were reported by Amgen to regulate lipolysis (eg. AMG7703/4-CMTB, Table 1, Figure 2). However, the clinical use of these drugs was deemed to be limited due to low solubility and poor pharmacokinetics (Wang et al., 2010). Orthosteric FFA2 agonists and antagonists have also now been reported (Hudson et al., 2012b, Hudson et al., 2013a) and used to demonstrate a role for this receptor in improved glucose uptake, decreased colon

motility and contractility, increased GLP-1 secretion and inhibiting leukocyte activation (Cornall et al., 2013, Ulven, 2012, Hudson et al., 2012a, Hudson et al., 2012b). FFA3 agonists are even less developed although Arena Pharmaceuticals has reported a series of FFA3-selective compounds (Ulven, 2012) (Table 1). Pharmacological characterisation of compounds from this series demonstrated that individual members have diverse pharmacological properties, acting as intrinsic agonists and/or allosterically modulating the potency or efficacy of the response to SCFA propionate (Hudson et al., 2014a). Hence, although recent microbiota studies highlight quite elegantly the role that gut-derived SCFAs can play in the regulation of metabolism, there still remains a great demand for improved FFA2 and FFA3 agonists to fully unravel and define the consequences of activation of these receptors for metabolic health.

Future perspectives

The withdrawal of FFA1 agonists from clinical trials, particularly Fasiglifam, highlights the critical importance of establishing whether the adverse effects reported during these clinical trials are due to FFA1 agonism or the chemical structures of the particular FFA1 agonists. Additionally, as FFA2, FFA3 and FFA4 agonists further develop and hopefully enter clinical trials, it will be interesting to see if the same issues highlighted during FFA1 trials will also arise. Future research should also fully address the relative effects of partial and full FFA1 agonists, particularly in relation to allosterism in conjunction with natural FFA ligands. Additionally, dual agonists of FFA1 and FFA4 may have enhanced effects on insulin secretion and insulin sensitivity compared to selective FFA1 or FFA4 agonists alone. Similarly, co-therapeutic approaches involving FFA receptor agonists and current T2D therapies should be examined. For example, the FFA1 agonist, AS2575959 (Table 1), acts synergistically with a DPP-IV inhibitor to improve glucose homeostasis (Tanaka et al., 2014) and combination therapy with Fasiglifam and metformin displayed enhanced anti-diabetic effects in a diabetic rat model (Ito et al., 2013). Similarly, the FFA1 agonist, DS-1558 (Table 1), acts synergistically with exendin-4, a GLP-1 receptor agonist, to improve glucose homeostasis in diabetic mice (Nakashima et al., 2014). Clearly, there are a number of significant challenges ahead in the development of clinical treatments based on FFA receptor agonism. However, should these challenges be met, FFA receptor agonism may provide a novel and effective way to treat T2D.

Non-standard Abbreviations

T2D, type 2 diabetes; GLP-1, glucagon-like peptide-1; DPP-4, dipeptidyl peptidase-4; FFA, free fatty acid, FFA1-4, Free Fatty Acid Receptors 1-4; SCFA, short chain fatty acid; MCFA, medium chain fatty acid; LCFA, long chain fatty acid; GPCR, G protein-coupled receptor; GSIS, glucose-stimulated insulin secretion; CNS, central nervous system; HFD, high fat diet; HbA1c, haemoglobin A1c; aLA, α linoleic acid, DHA, docosahexaenoic acid; LPS, lipopolysaccharide; TNF, tumour necrosis factor; PYY, peptide YY; GIP, glucose-dependent insulintropic polypeptide

Acknowledgements

This work is supported in part by grants from the Biotechnology and Biosciences Research Council [BB/K019864/1] (to G.M), a Canadian Institutes of Health

Research (fellowship to B.D.H.) and the Danish Council for Strategic Research grant [11-116196] (to T.U. and G.M.).

Conflict of interest statement

None

References

- ABDOUL-AZIZE, S., SELVAKUMAR, S., SADO, H., BESNARD, P. & KHAN, N. A. 2014. Ca²⁺ signaling in taste bud cells and spontaneous preference for fat: unresolved roles of CD36 and GPR120. *Biochimie*, 96, 8-13.
- ALBERTI, K. G. & ZIMMET, P. Z. 2014. Diabetes: a look to the future. *Lancet Diabetes Endocrinol*, 2, e1-2.
- ARAKI, T., HIRAYAMA, M., HIROI, S. & KAKU, K. 2012. GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. *Diabetes Obes Metab*, 14, 271-8.
- BAILEY, C. J. 2012. Could FFAR1 assist insulin secretion in type 2 diabetes? *Lancet*, 379, 1370-1.
- BINDELS, L. B., DEWULF, E. M. & DELZENNE, N. M. 2013. GPR43/FFA2: physiopathological relevance and therapeutic prospects. *Trends Pharmacol Sci*, 34, 226-32.
- BJURSELL, M., ADMYRE, T., GORANSSON, M., MARLEY, A. E., SMITH, D. M., OSCARSSON, J. & BOHLOOLY, Y. M. 2011. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. *Am J Physiol Endocrinol Metab*, 300, E211-20.
- BRISCOE, C. P., PEAT, A. J., MCKEOWN, S. C., CORBETT, D. F., GOETZ, A. S., LITTLETON, T. R., MCCOY, D. C., KENAKIN, T. P., ANDREWS, J. L., AMMALA, C., FORNWALD, J. A., IGNAR, D. M. & JENKINSON, S. 2006. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. *Br J Pharmacol*, 148, 619-28.
- BROWN, A. J., GOLDSWORTHY, S. M., BARNES, A. A., EILERT, M. M., TCHEANG, L., DANIELS, D., MUIR, A. I., WIGGLESWORTH, M. J., KINGHORN, I., FRASER, N. J., PIKE, N. B., STRUM, J. C., STEPLEWSKI, K. M., MURDOCK, P. R., HOLDER, J. C., MARSHALL, F. H., SZEKERES, P. G., WILSON, S., IGNAR, D. M., FOORD, S. M., WISE, A. & DOWELL, S. J. 2003. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem*, 278, 11312-9.
- BROWN, S. P., DRANSFIELD, P. J., VIMOLRATANA, M., JIAO, X., ZHU, L., PATTAROPONG, V., SUN, Y., LIU, J., LUO, J., ZHANG, J., WONG, S., ZHUANG, R., GUO, Q., LI, F., MEDINA, J. C., SWAMINATH, G., LIN, D. C. & HOUZE, J. B. 2012. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist. *ACS Med Chem Lett*, 3, 726-30.
- BURANT, C. F. 2013. Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes. *Diabetes Care*, 36 Suppl 2, S175-9.
- BURANT, C. F., VISWANATHAN, P., MARCINAK, J., CAO, C., VAKILYNEJAD, M., XIE, B. & LEIFKE, E. 2012. TAK-875 versus placebo or glimepiride in

495 type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-
 496 controlled trial. *Lancet*, 379, 1403-11.
 497 CANI, P. D., EVERARD, A. & DUPARC, T. 2013. Gut microbiota, enteroendocrine
 498 functions and metabolism. *Curr Opin Pharmacol*, 13, 935-40.
 499 CARTONI, C., YASUMATSU, K., OHKURI, T., SHIGEMURA, N., YOSHIDA, R.,
 500 GODINOT, N., LE COUTRE, J., NINOMIYA, Y. & DAMAK, S. 2010. Taste
 501 preference for fatty acids is mediated by GPR40 and GPR120. *J Neurosci*, 30,
 502 8376-82.
 503 CHRISTIANSEN, E., DUE-HANSEN, M. E., URBAN, C., GRUNDMANN, M.,
 504 SCHMIDT, J., HANSEN, S. V., HUDSON, B. D., ZAIBI, M., MARKUSSEN,
 505 S. B., HAGESAETHER, E., MILLIGAN, G., CAWTHORNE, M. A.,
 506 KOSTENIS, E., KASSACK, M. U. & ULVEN, T. 2013a. Discovery of a
 507 potent and selective free fatty acid receptor 1 agonist with low lipophilicity
 508 and high oral bioavailability. *J Med Chem*, 56, 982-92.
 509 CHRISTIANSEN, E., DUE-HANSEN, M. E., URBAN, C., GRUNDMANN, M.,
 510 SCHRODER, R., HUDSON, B. D., MILLIGAN, G., CAWTHORNE, M. A.,
 511 KOSTENIS, E., KASSACK, M. U. & ULVEN, T. 2012. Free fatty acid
 512 receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers
 513 lipophilicity and improves ADME properties. *J Med Chem*, 55, 6624-8.
 514 CHRISTIANSEN, E., DUE-HANSEN, M. E., URBAN, C., MERTEN, N.,
 515 PFLEIDERER, M., KARLSEN, K. K., RASMUSSEN, S. S.,
 516 STEENSGAARD, M., HAMACHER, A., SCHMIDT, J., DREWKE, C.,
 517 PETERSEN, R. K., KRISTIANSEN, K., ULLRICH, S., KOSTENIS, E.,
 518 KASSACK, M. U. & ULVEN, T. 2010. Structure-Activity Study of
 519 Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist
 520 TUG-469. *ACS Med Chem Lett*, 1, 345-9.
 521 CHRISTIANSEN, E., HANSEN, S. V., URBAN, C., HUDSON, B. D., WARGENT,
 522 E. T., GRUNDMANN, M., JENKINS, L., ZAIBI, M., STOCKER, C. J.,
 523 ULLRICH, S., KOSTENIS, E., KASSACK, M. U., MILLIGAN, G.,
 524 CAWTHORNE, M. A. & ULVEN, T. 2013b. Discovery of TUG-770: A
 525 Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for
 526 Treatment of Type 2 Diabetes. *ACS Med Chem Lett*, 4, 441-445.
 527 CHRISTIANSEN, E., URBAN, C., GRUNDMANN, M., DUE-HANSEN, M. E.,
 528 HAGESAETHER, E., SCHMIDT, J., PARDO, L., ULLRICH, S., KOSTENIS,
 529 E., KASSACK, M. & ULVEN, T. 2011. Identification of a potent and
 530 selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable
 531 physicochemical and in vitro ADME properties. *J Med Chem*, 54, 6691-703.
 532 CHRISTIANSEN, E., URBAN, C., MERTEN, N., LIEBSCHER, K., KARLSEN, K.
 533 K., HAMACHER, A., SPINRATH, A., BOND, A. D., DREWKE, C.,
 534 ULLRICH, S., KASSACK, M. U., KOSTENIS, E. & ULVEN, T. 2008.
 535 Discovery of potent and selective agonists for the free fatty acid receptor 1
 536 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. *J Med*
 537 *Chem*, 51, 7061-4.
 538 CINTRA, D. E., ROPELLE, E. R., MORAES, J. C., PAULI, J. R., MORARI, J.,
 539 SOUZA, C. T., GRIMALDI, R., STAHL, M., CARVALHEIRA, J. B., SAAD,
 540 M. J. & VELLOSO, L. A. 2012. Unsaturated fatty acids revert diet-induced
 541 hypothalamic inflammation in obesity. *PLoS One*, 7, e30571.
 542 CORNALL, L. M., MATHAI, M. L., HRYCIW, D. H. & MCAINCH, A. J. 2013.
 543 The therapeutic potential of GPR43: a novel role in modulating metabolic
 544 health. *Cell Mol Life Sci*, 70, 4759-70.

545 CORNALL, L. M., MATHAI, M. L., HRYCIW, D. H. & MCAINCH, A. J. 2014.
546 GPR120 agonism as a countermeasure against metabolic diseases. *Drug*
547 *Discov Today*, 19, 670-679.

548 DEFOSSA, E. & WAGNER, M. 2014. Recent developments in the discovery of
549 FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus.
550 *Bioorg Med Chem Lett*, 24, 2991-3000.

551 DEL GUERRA, S., BUGLIANI, M., D'ALEO, V., DEL PRATO, S., BOGGI, U.,
552 MOSCA, F., FILIPPONI, F. & LUPI, R. 2010. G-protein-coupled receptor 40
553 (GPR40) expression and its regulation in human pancreatic islets: the role of
554 type 2 diabetes and fatty acids. *Nutr Metab Cardiovasc Dis*, 20, 22-5.

555 EDFALK, S., STENEBERG, P. & EDLUND, H. 2008. Gpr40 is expressed in
556 enteroendocrine cells and mediates free fatty acid stimulation of incretin
557 secretion. *Diabetes*, 57, 2280-7.

558 ENGELSTOFT, M. S., PARK, W. M., SAKATA, I., KRISTENSEN, L. V., HUSTED,
559 A. S., OSBORNE-LAWRENCE, S., PIPER, P. K., WALKER, A. K.,
560 PEDERSEN, M. H., NOHR, M. K., PAN, J., SINZ, C. J., CARRINGTON, P.
561 E., AKIYAMA, T. E., JONES, R. M., TANG, C., AHMED, K.,
562 OFFERMANN, S., EGEROD, K. L., ZIGMAN, J. M. & SCHWARTZ, T. W.
563 2013. Seven transmembrane G protein-coupled receptor repertoire of gastric
564 ghrelin cells. *Mol Metab*, 2, 376-92.

565 FERDAOUSI, M., BERGERON, V., ZARROUKI, B., KOLIC, J., CANTLEY, J.,
566 FIELITZ, J., OLSON, E. N., PRENTKI, M., BIDEN, T., MACDONALD, P.
567 E. & POITOUT, V. 2012. G protein-coupled receptor (GPR)40-dependent
568 potentiation of insulin secretion in mouse islets is mediated by protein kinase
569 D1. *Diabetologia*, 55, 2682-92.

570 FLODGREN, E., OLDE, B., MEIDUTE-ABARAVICIENE, S., WINZELL, M. S.,
571 AHREN, B. & SALEHI, A. 2007. GPR40 is expressed in glucagon producing
572 cells and affects glucagon secretion. *Biochem Biophys Res Commun*, 354, 240-
573 5.

574 FONTES, G., ZARROUKI, B., HAGMAN, D. K., LATOUR, M. G., SEMACHE, M.,
575 ROSKENS, V., MOORE, P. C., PRENTKI, M., RHODES, C. J., JETTON, T.
576 L. & POITOUT, V. 2010. Glucolipotoxicity age-dependently impairs beta cell
577 function in rats despite a marked increase in beta cell mass. *Diabetologia*, 53,
578 2369-79.

579 GILBERTSON, T. A. & KHAN, N. A. 2014. Cell signaling mechanisms of oro-
580 gustatory detection of dietary fat: advances and challenges. *Prog Lipid Res*, 53,
581 82-92.

582 GONG, Z., YOSHIMURA, M., AIZAWA, S., KUROTANI, R., ZIGMAN, J. M.,
583 SAKAI, T. & SAKATA, I. 2014. G protein-coupled receptor 120 signaling
584 regulates ghrelin secretion in vivo and in vitro. *Am J Physiol Endocrinol*
585 *Metab*, 306, E28-35.

586 HALDER, S., KUMAR, S. & SHARMA, R. 2013. The therapeutic potential of
587 GPR120: a patent review. *Expert Opin Ther Pat*, 23, 1581-90.

588 HIRASAWA, A., ITSUBO, C., SADAKANE, K., HARA, T., SHINAGAWA, S.,
589 KOGA, H., NOSE, H., KOSHIMIZU, T. A. & TSUJIMOTO, G. 2008.
590 Production and characterization of a monoclonal antibody against GPR40
591 (FFAR1; free fatty acid receptor 1). *Biochem Biophys Res Commun*, 365, 22-8.

592 HIRASAWA, A., TSUMAYA, K., AWAJI, T., KATSUMA, S., ADACHI, T.,
593 YAMADA, M., SUGIMOTO, Y., MIYAZAKI, S. & TSUJIMOTO, G. 2005.

594 Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through
595 GPR120. *Nat Med*, 11, 90-4.

596 HOLLIDAY, N. D., WATSON, S. J. & BROWN, A. J. 2011. Drug discovery
597 opportunities and challenges at G protein coupled receptors for long chain free
598 Fatty acids. *Front Endocrinol (Lausanne)*, 2, 112.

599 HOUZE, J. B., ZHU, L., SUN, Y., AKERMAN, M., QIU, W., ZHANG, A. J.,
600 SHARMA, R., SCHMITT, M., WANG, Y., LIU, J., LIU, J., MEDINA, J. C.,
601 REAGAN, J. D., LUO, J., TONN, G., ZHANG, J., LU, J. Y., CHEN, M.,
602 LOPEZ, E., NGUYEN, K., YANG, L., TANG, L., TIAN, H.,
603 SHUTTLEWORTH, S. J. & LIN, D. C. 2012. AMG 837: a potent, orally
604 bioavailable GPR40 agonist. *Bioorg Med Chem Lett*, 22, 1267-70.

605 HUDSON, B. D., CHRISTIANSEN, E., MURDOCH, H., JENKINS, L., HANSEN,
606 A. H., MADSEN, O., ULVEN, T. & MILLIGAN, G. 2014a. Complex
607 pharmacology of novel allosteric free Fatty Acid 3 receptor ligands. *Mol*
608 *Pharmacol*, 86, 200-10.

609 HUDSON, B. D., CHRISTIANSEN, E., TIKHONOVA, I. G., GRUNDMANN, M.,
610 KOSTENIS, E., ADAMS, D. R., ULVEN, T. & MILLIGAN, G. 2012a.
611 Chemically engineering ligand selectivity at the free fatty acid receptor 2
612 based on pharmacological variation between species orthologs. *FASEB J*, 26,
613 4951-65.

614 HUDSON, B. D., DUE-HANSEN, M. E., CHRISTIANSEN, E., HANSEN, A. M.,
615 MACKENZIE, A. E., MURDOCH, H., PANDEY, S. K., WARD, R. J.,
616 MARQUEZ, R., TIKHONOVA, I. G., ULVEN, T. & MILLIGAN, G. 2013a.
617 Defining the molecular basis for the first potent and selective orthosteric
618 agonists of the FFA2 free fatty acid receptor. *J Biol Chem*, 288, 17296-312.

619 HUDSON, B. D., SHIMPUKADE, B., MACKENZIE, A. E., BUTCHER, A. J.,
620 PEDIANI, J. D., CHRISTIANSEN, E., HEATHCOTE, H., TOBIN, A. B.,
621 ULVEN, T. & MILLIGAN, G. 2013b. The pharmacology of TUG-891, a
622 potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120),
623 demonstrates both potential opportunity and possible challenges to therapeutic
624 agonism. *Mol Pharmacol*, 84, 710-25.

625 HUDSON, B. D., SHIMPUKADE, B., MILLIGAN, G. & ULVEN, T. 2014b. The
626 Molecular Basis of Ligand Interaction at Free Fatty Acid Receptor 4
627 (FFA4/GPR120). *J Biol Chem*, 289, 20345-20358.

628 HUDSON, B. D., TIKHONOVA, I. G., PANDEY, S. K., ULVEN, T. & MILLIGAN,
629 G. 2012b. Extracellular ionic locks determine variation in constitutive activity
630 and ligand potency between species orthologs of the free fatty acid receptors
631 FFA2 and FFA3. *J Biol Chem*, 287, 41195-209.

632 ICHIMURA, A., HIRASAWA, A., POULAIN-GODEFROY, O., BONNEFOND, A.,
633 HARA, T., YENGO, L., KIMURA, I., LELOIRE, A., LIU, N., IIDA, K.,
634 CHOQUET, H., BESNARD, P., LECOEUR, C., VIVEQUIN, S.,
635 AYUKAWA, K., TAKEUCHI, M., OZAWA, K., TAUBER, M., MAFFEIS,
636 C., MORANDI, A., BUZZETTI, R., ELLIOTT, P., POUTA, A., JARVELIN,
637 M. R., KORNER, A., KIESS, W., PIGEYRE, M., CAIAZZO, R., VAN HUL,
638 W., VAN GAAL, L., HORBER, F., BALKAU, B., LEVY-MARCHAL, C.,
639 ROUSKAS, K., KOUVATSI, A., HEBEBRAND, J., HINNEY, A.,
640 SCHERAG, A., PATTOU, F., MEYRE, D., KOSHIMIZU, T. A.,
641 WOLOWCZUK, I., TSUJIMOTO, G. & FROGUEL, P. 2012. Dysfunction of
642 lipid sensor GPR120 leads to obesity in both mouse and human. *Nature*, 483,
643 350-4.

- ITO, R., TSUJIHATA, Y., MATSUDA-NAGASUMI, K., MORI, I., NEGORO, N. & TAKEUCHI, K. 2013. TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and beta-cell dysfunction in Zucker diabetic fatty rats. *Br J Pharmacol*, 170, 568-80.
- ITOH, Y., KAWAMATA, Y., HARADA, M., KOBAYASHI, M., FUJII, R., FUKUSUMI, S., OGI, K., HOSOYA, M., TANAKA, Y., UEJIMA, H., TANAKA, H., MARUYAMA, M., SATOH, R., OKUBO, S., KIZAWA, H., KOMATSU, H., MATSUMURA, F., NOGUCHI, Y., SHINOHARA, T., HINUMA, S., FUJISAWA, Y. & FUJINO, M. 2003. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. *Nature*, 422, 173-6.
- KEBEDE, M., FERDAOUSSE, M., MANCINI, A., ALQUIER, T., KULKARNI, R. N., WALKER, M. D. & POITOUT, V. 2012. Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol-3-kinase-dependent O-GlcNAcylation of pancreas-duodenum homeobox-1. *Proc Natl Acad Sci U S A*, 109, 2376-81.
- KIMURA, I., OZAWA, K., INOUE, D., IMAMURA, T., KIMURA, K., MAEDA, T., TERASAWA, K., KASHIHARA, D., HIRANO, K., TANI, T., TAKAHASHI, T., MIYAUCHI, S., SHIOI, G., INOUE, H. & TSUJIMOTO, G. 2013. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. *Nat Commun*, 4, 1829.
- LAN, H., HOOS, L. M., LIU, L., TETZLOFF, G., HU, W., ABBONDANZO, S. J., VASSILEVA, G., GUSTAFSON, E. L., HEDRICK, J. A. & DAVIS, H. R. 2008. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. *Diabetes*, 57, 2999-3006.
- LATOUR, M. G., ALQUIER, T., OSEID, E., TREMBLAY, C., JETTON, T. L., LUO, J., LIN, D. C. & POITOUT, V. 2007. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. *Diabetes*, 56, 1087-94.
- LE POUL, E., LOISON, C., STRUYF, S., SPRINGAEL, J. Y., LANNON, V., DECOBECQ, M. E., BREZILLON, S., DUPRIEZ, V., VASSART, G., VAN DAMME, J., PARMENTIER, M. & DETHEUX, M. 2003. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. *J Biol Chem*, 278, 25481-9.
- LEIFKE, E., NAIK, H., WU, J., VISWANATHAN, P., DEMANNO, D., KIPNES, M. & VAKILYNEJAD, M. 2012. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. *Clin Pharmacol Ther*, 92, 29-39.
- LI, X., YU, Y. & FUNK, C. D. 2013. Cyclooxygenase-2 induction in macrophages is modulated by docosahexaenoic acid via interactions with free fatty acid receptor 4 (FFA4). *FASEB J*, 27, 4987-97.
- LIN, D. C., GUO, Q., LUO, J., ZHANG, J., NGUYEN, K., CHEN, M., TRAN, T., DRANSFIELD, P. J., BROWN, S. P., HOUZE, J., VIMOLRATANA, M., JIAO, X. Y., WANG, Y., BIRDSALL, N. J. & SWAMINATH, G. 2012a. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. *Mol Pharmacol*, 82, 843-59.
- LIN, H. V., FRASSETTO, A., KOWALIK, E. J., JR., NAWROCKI, A. R., LU, M. M., KOSINSKI, J. R., HUBERT, J. A., SZETO, D., YAO, X., FORREST, G. & MARSH, D. J. 2012b. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. *PLoS One*, 7, e35240.

- LIU, A. P., LU, X., SEI, Y., ZHAO, X., PECHHOLD, S., CARRERO, R. J.,
RAYBOULD, H. E. & WANK, S. 2011. The G-protein-coupled receptor
GPR40 directly mediates long-chain fatty acid-induced secretion of
cholecystokinin. *Gastroenterology*, 140, 903-12.
- LUO, J., SWAMINATH, G., BROWN, S. P., ZHANG, J., GUO, Q., CHEN, M.,
NGUYEN, K., TRAN, T., MIAO, L., DRANSFIELD, P. J.,
VIMOLRATANA, M., HOUZE, J. B., WONG, S., TOTEVA, M., SHAN, B.,
LI, F., ZHUANG, R. & LIN, D. C. 2012. A potent class of GPR40 full
agonists engages the enteroinsular axis to promote glucose control in rodents.
PLoS One, 7, e46300.
- MA, D., TAO, B., WARASHINA, S., KOTANI, S., LU, L., KAPLAMADZHIEV, D.
B., MORI, Y., TONCHEV, A. B. & YAMASHIMA, T. 2007. Expression of
free fatty acid receptor GPR40 in the central nervous system of adult monkeys.
Neurosci Res, 58, 394-401.
- MAJUMDAR, S. K. & INZUCCHI, S. E. 2013. Investigational anti-hyperglycemic
agents: the future of type 2 diabetes therapy? *Endocrine*, 44, 47-58.
- MANCINI, A. D. & POITOUT, V. 2013. The fatty acid receptor FFA1/GPR40 a
decade later: how much do we know? *Trends Endocrinol Metab*, 24, 398-407.
- MCCARTHY, M. I. 2010. Genomics, type 2 diabetes, and obesity. *N Engl J Med*, 363,
2339-50.
- NAGASUMI, K., ESAKI, R., IWACHIDOW, K., YASUHARA, Y., OGI, K.,
TANAKA, H., NAKATA, M., YANO, T., SHIMAKAWA, K., TAKETOMI,
S., TAKEUCHI, K., ODAKA, H. & KAISHO, Y. 2009. Overexpression of
GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion
and improves glucose tolerance in normal and diabetic mice. *Diabetes*, 58,
1067-76.
- NAIK, H., VAKILYNEJAD, M., WU, J., VISWANATHAN, P., DOTE, N.,
HIGUCHI, T. & LEIFKE, E. 2012. Safety, tolerability, pharmacokinetics, and
pharmacodynamic properties of the GPR40 agonist TAK-875: results from a
double-blind, placebo-controlled single oral dose rising study in healthy
volunteers. *J Clin Pharmacol*, 52, 1007-16.
- NAKAMOTO, K., NISHINAKA, T., SATO, N., MANKURA, M., KOYAMA, Y.,
KASUYA, F. & TOKUYAMA, S. 2013. Hypothalamic GPR40 signaling
activated by free long chain fatty acids suppresses CFA-induced inflammatory
chronic pain. *PLoS One*, 8, e81563.
- NAKASHIMA, R., YANO, T., OGAWA, J., TANAKA, N., TODA, N., YOSHIDA,
M., TAKANO, R., INOUE, M., HONDA, T., KUME, S. & MATSUMOTO,
K. 2014. Potentiation of insulin secretion and improvement of glucose
intolerance by combining a novel G protein-coupled receptor 40 agonist DS-
1558 with glucagon-like peptide-1 receptor agonists. *Eur J Pharmacol*, 737C,
194-201.
- NILSSON, N. E., KOTARSKY, K., OWMAN, C. & OLDE, B. 2003. Identification
of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by
short-chain fatty acids. *Biochem Biophys Res Commun*, 303, 1047-52.
- NOHR, M. K., PEDERSEN, M. H., GILLE, A., EGEROD, K. L., ENGELSTOFT, M.
S., HUSTED, A. S., SICHLAU, R. M., GRUNDDAL, K. V., POULSEN, S. S.,
HAN, S., JONES, R. M., OFFERMANN, S. & SCHWARTZ, T. W. 2013.
GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in
enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric
leukocytes. *Endocrinology*, 154, 3552-64.

- OFFERMANN, S. 2014. Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors. *Annu Rev Pharmacol Toxicol*, 54, 407-34.
- OH, D. Y., TALUKDAR, S., BAE, E. J., IMAMURA, T., MORINAGA, H., FAN, W., LI, P., LU, W. J., WATKINS, S. M. & OLEFSKY, J. M. 2010. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. *Cell*, 142, 687-98.
- PAULSEN, S. J., LARSEN, L. K., HANSEN, G., CHELUR, S., LARSEN, P. J. & VRANG, N. 2014. Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion. *PLoS One*, 9, e88227.
- POITOUT, V. & LIN, D. C. 2013. Modulating GPR40: therapeutic promise and potential in diabetes. *Drug Discov Today*, 18, 1301-8.
- SAMUEL, B. S., SHAITO, A., MOTOIKE, T., REY, F. E., BACKHED, F., MANCHESTER, J. K., HAMMER, R. E., WILLIAMS, S. C., CROWLEY, J., YANAGISAWA, M. & GORDON, J. I. 2008. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. *Proc Natl Acad Sci U S A*, 105, 16767-72.
- SCHMIDT, J., SMITH, N. J., CHRISTIANSEN, E., TIKHONOVA, I. G., GRUNDMANN, M., HUDSON, B. D., WARD, R. J., DREWKE, C., MILLIGAN, G., KOSTENIS, E. & ULVEN, T. 2011. Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. *J Biol Chem*, 286, 10628-40.
- SHIMPUKADE, B., HUDSON, B. D., HOVGAARD, C. K., MILLIGAN, G. & ULVEN, T. 2012. Discovery of a potent and selective GPR120 agonist. *J Med Chem*, 55, 4511-5.
- SPARKS, S. M., CHEN, G., COLLINS, J. L., DANGER, D., DOCK, S. T., JAYAWICKREME, C., JENKINSON, S., LAUDEMAN, C., LEESNITZER, M. A., LIANG, X., MALONEY, P., MCCOY, D. C., MONCOL, D., RASH, V., RIMELE, T., VULIMIRI, P., WAY, J. M. & ROSS, S. 2014. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). *Bioorg Med Chem Lett*, 24, 3100-3.
- STENEBERG, P., RUBINS, N., BARTOEV-SHIFMAN, R., WALKER, M. D. & EDLUND, H. 2005. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. *Cell Metab*, 1, 245-58.
- STONE, V. M., DHAYAL, S., BROCKLEHURST, K. J., LENAGHAN, C., SORHEDE WINZELL, M., HAMMAR, M., XU, X., SMITH, D. M. & MORGAN, N. G. 2014. GPR120 (FFAR4) is preferentially expressed in pancreatic delta cells and regulates somatostatin secretion from murine islets of Langerhans. *Diabetologia*, 57, 1182-91.
- SUCKOW, A. T., POLIDORI, D., YAN, W., CHON, S., MA, J. Y., LEONARD, J. & BRISCOE, C. P. 2014. Alteration of the Glucagon Axis in GPR120 (FFAR4) Knockout Mice: A ROLE FOR GPR120 IN GLUCAGON SECRETION. *J Biol Chem*, 289, 15751-15763.
- TAKANO, R., YOSHIDA, M., INOUE, M., HONDA, T., NAKASHIMA, R., MATSUMOTO, K., YANO, T., OGATA, T., WATANABE, N. & TODA, N. 2014. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists. *Bioorg Med Chem Lett*, 24, 2949-53.
- TANAKA, H., YOSHIDA, S., MINOURA, H., NEGORO, K., SHIMAYA, A., SHIMOKAWA, T. & SHIBASAKI, M. 2014. Novel GPR40 agonist

793 AS2575959 exhibits glucose metabolism improvement and synergistic effect
794 with sitagliptin on insulin and incretin secretion. *Life Sci*, 94, 115-21.

795 TANAKA, H., YOSHIDA, S., OSHIMA, H., MINOURA, H., NEGORO, K.,
796 YAMAZAKI, T., SAKUDA, S., IWASAKI, F., MATSUI, T. & SHIBASAKI,
797 M. 2013. Chronic treatment with novel GPR40 agonists improve whole-body
798 glucose metabolism based on the glucose-dependent insulin secretion. *J*
799 *Pharmacol Exp Ther*, 346, 443-52.

800 TANEERA, J., LANG, S., SHARMA, A., FADISTA, J., ZHOU, Y., AHLQVIST, E.,
801 JONSSON, A., LYSSENKO, V., VIKMAN, P., HANSSON, O., PARIKH, H.,
802 KORSGREN, O., SONI, A., KRUS, U., ZHANG, E., JING, X. J.,
803 ESGUERRA, J. L., WOLLHEIM, C. B., SALEHI, A., ROSENGREN, A.,
804 RENSTROM, E. & GROOP, L. 2012. A systems genetics approach identifies
805 genes and pathways for type 2 diabetes in human islets. *Cell Metab*, 16, 122-
806 34.

807 TOLHURST, G., HEFFRON, H., LAM, Y. S., PARKER, H. E., HABIB, A. M.,
808 DIAKOIANNAKI, E., CAMERON, J., GROSSE, J., REIMANN, F. &
809 GRIBBLE, F. M. 2012. Short-chain fatty acids stimulate glucagon-like
810 peptide-1 secretion via the G-protein-coupled receptor FFAR2. *Diabetes*, 61,
811 364-71.

812 TSUJIHATA, Y., ITO, R., SUZUKI, M., HARADA, A., NEGORO, N., YASUMA,
813 T., MOMOSE, Y. & TAKEUCHI, K. 2011. TAK-875, an orally available G
814 protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances
815 glucose-dependent insulin secretion and improves both postprandial and
816 fasting hyperglycemia in type 2 diabetic rats. *J Pharmacol Exp Ther*, 339,
817 228-37.

818 ULVEN, T. 2012. Short-chain free fatty acid receptors FFA2/GPR43 and
819 FFA3/GPR41 as new potential therapeutic targets. *Front Endocrinol*
820 *(Lausanne)*, 3, 111.

821 URBAN, C., HAMACHER, A., PARTKE, H. J., RODEN, M., SCHINNER, S.,
822 CHRISTIANSEN, E., DUE-HANSEN, M. E., ULVEN, T., GOHLKE, H. &
823 KASSACK, M. U. 2013. In vitro and mouse in vivo characterization of the
824 potent free fatty acid 1 receptor agonist TUG-469. *Naunyn Schmiedebergs*
825 *Arch Pharmacol*, 386, 1021-30.

826 WAGNER, R., KAISER, G., GERST, F., CHRISTIANSEN, E., DUE-HANSEN, M.
827 E., GRUNDMANN, M., MACHICAO, F., PETER, A., KOSTENIS, E.,
828 ULVEN, T., FRITSCH, A., HARING, H. U. & ULLRICH, S. 2013.
829 Reevaluation of fatty acid receptor 1 as a drug target for the stimulation of
830 insulin secretion in humans. *Diabetes*, 62, 2106-11.

831 WALKER, C. G., GOFF, L., BLUCK, L. J., GRIFFIN, B. A., JEBB, S. A.,
832 LOVEGROVE, J. A., SANDERS, T. A., FROST, G. S. & GROUP, R. S.
833 2011. Variation in the FFAR1 gene modifies BMI, body composition and
834 beta-cell function in overweight subjects: an exploratory analysis. *PLoS One*,
835 6, e19146.

836 WANG, L., ZHAO, Y., GUI, B., FU, R., MA, F., YU, J., QU, P., DONG, L. &
837 CHEN, C. 2011. Acute stimulation of glucagon secretion by linoleic acid
838 results from GPR40 activation and [Ca²⁺]_i increase in pancreatic islet
839 {α}-cells. *J Endocrinol*, 210, 173-9.

840 WANG, Y., JIAO, X., KAYSER, F., LIU, J., WANG, Z., WANSKA, M.,
841 GREENBERG, J., WEISZMANN, J., GE, H., TIAN, H., WONG, S.,
842 SCHWANDNER, R., LEE, T. & LI, Y. 2010. The first synthetic agonists of

- 843 FFA2: Discovery and SAR of phenylacetamides as allosteric modulators.
844 *Bioorg Med Chem Lett*, 20, 493-8.
- 845 WANG, Y., LIU, J., DRANSFIELD, P. J., ZHU, L., WANG, Z., DU, X., JIAO, X.,
846 SU, Y., LI, A.-R., BROWN, S. P., KASPARIAN, A., VIMOLRATANA, M.,
847 YU, M., PATTAROPONG, V., HOUZE, J. B., SWAMINATH, G., TRAN, T.,
848 NGUYEN, K., GUO, Q., ZHANG, J., ZHUANG, R., LI, F., MIAO, L.,
849 BARTBERGER, M. D., CORRELL, T. L., CHOW, D., WONG, S., LUO, J.,
850 LIN, D. C. H. & MEDINA, J. C. 2013. Discovery and Optimization of Potent
851 GPR40 Full Agonists Containing Tricyclic Spirocycles. *ACS Medicinal*
852 *Chemistry Letters*, 4, 551-555.
- 853 WELLHAUSER, L. & BELSHAM, D. D. 2014. Activation of the omega-3 fatty acid
854 receptor GPR120 mediates anti-inflammatory actions in immortalized
855 hypothalamic neurons. *J Neuroinflammation*, 11, 60.
- 856 WU, P., YANG, L. & SHEN, X. 2010. The relationship between GPR40 and
857 lipotoxicity of the pancreatic beta-cells as well as the effect of pioglitazone.
858 *Biochem Biophys Res Commun*, 403, 36-9.
- 859 YASHIRO, H., TSUJIHATA, Y., TAKEUCHI, K., HAZAMA, M., JOHNSON, P. R.
860 & RORSMAN, P. 2012. The effects of TAK-875, a selective G protein-
861 coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion
862 in isolated rat and human islets. *J Pharmacol Exp Ther*, 340, 483-9.
- 863 ZAIBI, M. S., STOCKER, C. J., O'DOWD, J., DAVIES, A., BELLAHCENE, M.,
864 CAWTHORNE, M. A., BROWN, A. J., SMITH, D. M. & ARCH, J. R. 2010.
865 Roles of GPR41 and GPR43 in leptin secretory responses of murine
866 adipocytes to short chain fatty acids. *FEBS Lett*, 584, 2381-6.
- 867 ZHANG, Y., XU, M., ZHANG, S., YAN, L., YANG, C., LU, W., LI, Y. & CHENG,
868 H. 2007. The role of G protein-coupled receptor 40 in lipoapoptosis in mouse
869 beta-cell line NIT-1. *J Mol Endocrinol*, 38, 651-61.

Table 1: FFA receptor agonists for the treatment of T2D

Table 1 illustrates the most commonly described natural and synthetic ligands for FFA1-4. The current clinical status of these synthetic agonists for the treatment of T2D is also described.

FFA Receptor	Agonists	Metabolic Effects	Clinical Trial Status
FFA1	<p>Natural Ligands: palmitic acid, oleic acid, linoleic acid</p> <p>Synthetic ligands: GW9508, TAK-875/Fasiglifam, AMG-837, AM-1638, AM-5262, LY2881835, JTT-851, P11187, TUG-469, TUG-424, TUG-770, AS2575959, DS-1558</p>	<p>Improved fasting hypoglycaemia and glucose tolerance in diabetic animal models</p> <p>Increased GSIS</p> <p>Increased incretin release (full agonists: AM-1638, AM-5262, LY2881835)</p> <p>No associated hypoglycaemia in normoglycaemic rats</p>	<p>TAK-875/Fasiglifam (Takeda): Phase I/II trials showed reduced blood glucose levels, increased insulin levels, 1.2-1.4% reduction in HbA1c levels with no associated weight gain/hypoglycaemia in T2D patients. Removed from Phase III trials due to potential liver toxicity</p> <p>AMG-837 (Amgen) and LY2881835 (Eli Lilly): removed from Phase I trials due to toxicity</p> <p>JTT-851 (Japan Tobacco): currently in Phase II trials</p> <p>P11187(Piramal): currently in Phase I trials</p>
FFA2	<p>Natural ligands: acetate (preferred), propionate, butyrate</p> <p>Synthetic ligands: AMG7703/4-CMTB, Euroscreen compounds, compounds 1 and 2</p>	<p>Improved glucose uptake</p> <p>Decreased colon motility/contractility</p> <p>Increased GLP-1 secretion</p> <p>Inhibition of leukocyte activation</p>	No agonists currently in clinical trials
FFA3	<p>Natural ligands: propionate (preferred), butyrate, acetate</p> <p>Synthetic ligands: Arena Pharmaceuticals series</p>	Increased GLP-1 secretion	No agonists currently in clinical trials
FFA4	<p>Natural ligands: alpha-linolenic acid (αLA), docosahexanoic acid (DHA)</p> <p>Synthetic ligands: GW9508, NCG21, NCG46, TUG-891</p>	<p>Protection against diet-induced obesity</p> <p>Improved insulin sensitivity and glycaemic control</p> <p>Increased GLP-1 release</p> <p>Increased insulin secretion (largely attributed to GLP-1 release)</p> <p>Reduced inflammation</p>	No compounds currently in clinical trials although a number of companies have patented FFA4 agonists for the treatment of T2D (Banyu Pharmaceutical, Metabolex, Kindex Therapeutics, Pharma Frontier)

Figure 1: The biological effects of FFA receptors

Dietary FFAs, such as ω -3 fatty acids from fish oils and SCFAs derived from the fermentation of dietary fibre, have profound effects on metabolic and inflammatory processes associated with obesity and T2D. These effects have, at least in part, been attributed to the activation of Free Fatty Acid receptors (FFA1-4), leading to a great deal of interest in the development of synthetic FFA receptor agonists for the treatment of metabolic disease. Agonism of the long chain FFA receptor FFA1, the most fully characterised of these receptors, improves glucose-stimulated insulin secretion from the pancreas. Additionally, full agonists of this receptor increase incretin release from the gut, thereby indirectly increasing pancreatic insulin secretion, as well as improving systemic insulin sensitivity and promoting satiety. Agonism of another long chain FFA receptor, FFA4, is associated with incretin release from the gut, as well as an anti-inflammatory effect on macrophages that, in turn, may improve systemic insulin sensitivity. In the pancreas, FFA4 is associated with reduced cell apoptosis and FFA4 has recently been detected in alpha and delta cells and regulates glucagon and somatostatin release respectively. Both FFA1 and FFA4 have been detected in taste buds although the full implications of this in relation to obesity remains to be determined. The SCFA receptors, FFA2/FFA3, have recently been linked with the beneficial metabolic effects associated probiotics within the gut. Both receptors have been linked with incretin release from enteroendocrine cells, as well as both systemic anti- and pro-inflammatory effects. However, due to conflicting results using receptor-specific knock out models and a limited selection of pharmacological tools, more work is required to elucidate the physiological effects of FFA2 and FFA3 agonism.

Figure 2: Representative Free Fatty Acid receptor agonists

A number of academic and industrial drug programmes are aimed at developing FFA receptor agonists for the treatment of T2D. Figure 2 illustrates a representative selection of the current range of synthetic agonists that have so far been developed for these receptors.







Figure 2.JPEG


FFA1



FFA4



FFA2



FFA3

